PFM Health Sciences’s DaVita DVA Stock Holding History

PFM Health Sciences’s Portfolio DVA Stock Details DVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-420,400	Closed	-$29.2M	–	124
2018 Q2	$29.2M	Buy	+420,400	New	+$28.1M	0.46%	77

Other funds holding DVA

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

GCM

Gates Capital Management New York $3.66B AUM 12.63% 1-Year Est. Return

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PFM Health Sciences's DVA Position: Q1 2019 in Review

PFM Health Sciences sold out of DaVita (DVA) in Q1 2019, closing a stake of 962,234 shares — an estimated $49.5M sold.

PFM Health Sciences first reported a position in DVA in Q1 2016 and held it in 6 quarters. The position peaked at $107M in Q3 2018. 440 funds tracked by Wall St. Rank hold DVA as of Q1 2019.

PFM Health Sciences reported no remaining DaVita position as of Q1 2019 after selling out during the quarter.
PFM Health Sciences sold 962,234 DaVita shares in Q1 2019, an estimated $49.5M.
PFM Health Sciences first reported a position in DaVita in Q1 2016 and held it in 6 quarters.
PFM Health Sciences's DaVita position peaked at $107M in Q3 2018.
440 funds tracked by Wall St. Rank held DaVita as of Q1 2019.

Based on PFM Health Sciences's 13F filing for Q1 2019, filed 15 May 2019.